John B. Landis - 03 Jan 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Reporting relationship
Director
Issuer ticker
EYPT
Reported as of
03 Jan 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 Jan 2025, 16:04:03 UTC
Prior SEC filing
09 Jan 2024
Next SEC filing
06 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ron Honig, Attorney-in-Fact

Key filing fact

John B. Landis filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 07 Jan 2025.

Key facts

  • This page summarizes John B. Landis's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 07 Jan 2025, 16:04.

Change

  • Previous filing in this sequence was filed on 09 Jan 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EYPT transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+10,000
Change %
+88%
Price
$0.000000
Shares after
21,400
Date
05 Jan 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EYPT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+40,000
Change %
Price
$0.000000
Shares after
40,000
Date
03 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,000
Exercise price
$8.26
EYPT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-10,000
Change %
-100%
Price
$0.000000
Shares after
0
Date
05 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$0.000000
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Fully vested on the one-year anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .